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Dushinsky et al. left a great gift to human beings with the discovery of 5-ﬂuorouracil (5-FU).
Approximately 50 years have elapsed from that discovery to the development of S-1 (TS-1
w).
The concept of developing an anticancer agent that simultaneously possesses both efﬁcacy-
enhancing and adverse reaction-reducing effects could be achieved only with a three-
component combination drug. S-1 is an oral anticancer agent containing two biochemical
modulators for 5-FU and tegafur (FT), a metabolically activated prodrug of 5-FU. The ﬁrst
modulator, 5-chloro-2,4-dihydroxypyridine (CDHP), enhances the pharmacological actions of
5-FU by potently inhibiting its degradation. The second modulator, potassium oxonate (Oxo),
localizing in mucosal cells of the gastrointestinal (GI) tract after oral administration, reduces
the incidence of GI toxicities by suppressing the activation of 5-FU in the GI tract. Thus, S-1
combines FT, CDHP and Oxo at a molar ratio of 1:0.4:1. In 1999–2007, S-1 was approved
for the treatment of the following seven cancers: gastric, head and neck, colorectal, non-
small cell lung, breast, pancreatic and biliary tract cancers. ‘S-1 and low-dose cisplatin
therapy’ without provoking Grade 3 non-hematologic toxicities was proposed to enhance
its clinical usefulness. Furthermore, ‘alternate-day S-1 regimen’ may improve the dosing
schedule for 5-FU by utilizing its strongly time-dependent mode of action; the former is
characterized by the low incidences of myelotoxicity and non-hematologic toxicities
(e.g.  Grade 1 anorexia, fatigue, stomatitis, nausea, vomiting and taste alteration). These
two approaches are considered to allow long-lasting therapy with S-1.
Key words: 5-FU (5-ﬂuorouracil) – S-1 (TS-1
w) – balancing efﬁcacy and toxicity – S-1 and
low-dose CDDP therapy – alternate-day S-1 regimen
INTRODUCTION
The history of cancer chemotherapy started with the use of
nitrogen mustards, derivatives of poisonous gas (Yperite),
in 1943 during World War II as a therapeutic drug for
Hodgkin’s disease and leukemias by Goodman et al. (1).
Treatment with nitrogen mustards aimed to utilize the antitu-
mor activity of the drugs through their toxicities (e.g. leuko-
penia, diarrhea and stomatitis) in human beings. Numerous
novel compounds entered the ﬁeld of cancer chemotherapy
for solid tumors since then, including mitomycin discovered
by Hata et al. (2) and 5-ﬂuorouracil (5-FU) discovered by
Dushinsky et al. (3). In 1970–90s, when multidrug com-
bined consolidation therapy was conducted, combined antic-
ancer agents differing in mechanisms of action without
deﬁnite theoretical evidence and easily provoking adverse
reactions were developed, therefore, consolidation therapy
may be considered as a short-term decisive therapeutic
modality. Especially, such therapy not only provides rela-
tively high response rates but also presents proportionally
increased incidences of adverse reactions, resulting in failure
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Therefore, none of the entities completely satisﬁed
our demands, and concern about the efﬁcacy of cancer
chemotherapy emerged. In consequence, an increasing need
emerged for a therapeutic modality that is patient-friendly
and beneﬁcial, and a broad array of explorations has been
made for a novel drug or combination therapy with a new
mechanism of action or a new therapeutic concept in
response to the relevant need.
Acceptable international standard regimens for gastrointes-
tinal (GI) cancers were established as follows: in 1980,
5-FU, doxorubicin and mitomycin (FAM) (4) therapy for
gastric cancer; and in 1989, continuous venous infusion
(CVI) of 5-FU therapy for colorectal cancer (5). All these
treatments combined three or more anticancer agents, and
5-FU has been used as the core drug in all the regimens except
etoposide, doxorubicin and cisplatin (EAP) therapy (6).
Approximately 50 years have elapsed since the discovery
of 5-FU in 1957 before eventually elucidating the mechan-
isms by which the drug exerts its pharmacological actions
and provokes its adverse reactions.
Since 1990, however, we expanded the conventional
concept of using a single anticancer agent to overcome a
contradictory issue of exerting high anticancer activity and
provoking less adverse reactions in a simultaneous manner,
and ﬁnally concretized a novel, patient-friendly, long-lasting
therapeutic modality that would replace the conventional
concept. I describe here the following two topics on the
background of biochemical research on the efﬁcacy and
toxicity of 5-FU over the last 50 years and balancing them.
(i) History covering: (a) the synthesis of 5-FU and the dis-
covery of its antitumor activity, (b) the developments of
the ﬁrst masked form oral anticancer agent of 5-FU and
tegafur (FT) and of a combination between FT and
uracil—UFT
w and (c) the development of a combination
of FT, 5-chloro-2,4-dihydroxypyridine (CDHP) and pot-
assium oxonate (Oxo)—S-1 (TS-1
w).
(ii) Clinical usefulness and future vistas of S-1.
HISTORY COVERING THE SYNTHESIS OF
5-FU AND DISCOVERY OF ITS ANTITUMOR
ACTIVITY
TIMELINE: FROM THE DISCOVERY OF 5-FU TO THE DEVELOPMENT
OF S-1 (TS-1
w)
Dushinsky et al. (3) left a great gift to human beings. I refer
to the timeline covering an  50-year history from the
discovery of 5-FU to the development of S-1 (TS-1
w).
As shown in Table 1, there were four major inventions
and encounters from the discovery of 5-FU to the develop-
ment of S-1.
(i) In 1957, Dushinsky et al. (3) synthesized 5-FU and dis-
covered its antitumor activity. In many studies conducted by
them, they discovered that uracil and 5-FU more preferably
concentrate into tumor cells than other pyrimidine bases.
Therefore, they synthesized 5-FU in which hydrogen at ﬁve
positions in uracil was substituted with ﬂuorine. This ﬁnding
is very important to establish the optimal schedule for 5-FU
administration. Therefore, it is easy to predict that the long-
term exposure of 5-FU to tumor cells induces high cytotox-
icity and totally kills them.
Wilkoff et al. (7), Skipper et al. (8) and Shimoyama and
Kimura (9) concluded, based on the results from their
in vitro studies, that 5-FU is a typical antimetabolite with a
strongly time-dependent mode of action. Skipper et al. (8)
also suggested that a longer interval among doses than the
S-phase of the cell cycle is preferable for agents, e.g. 5-FU,
which are S-phase-speciﬁc but self-limiting with respect to
cytotoxicity. Shimoyama and Kimura examined the features
of cell death induced by 5-FU and discovered that cytotox-
icity during long-term exposure at a low concentration
induces marked reproductive or clonal death. Namely, cell
death was observed while microscopic small colonies were
formed during four or ﬁve cell divisions. Furthermore, they
stressed that long-term repeated exposure to cancer cells is a
very important factor for the dosing schedule for 5-FU (9).
Until  2000, CVI was considered to be the best schedule
for 5-FU administration (5,10).
However, the adverse reactions of 5-FU differ largely in
nature between the bolus and CVI regimens. The dose-
limiting toxicities of 5-FU are represented by myelotoxicity
in the bolus regimen, and by GI toxicities (e.g. diarrhea and
stomatitis) and hand–foot syndrome (HFS) in the CVI
regimen (5,10). To establish a highly useful therapeutic
modality with an aim to conduct long-lasting treatment with
5-FU, therefore, it is crucially important to devise a regimen
that provides a good balancing of its adverse reactions, e.g.
GI toxicities and HFS causing great discomfort for patients,
and its antitumor activity in cancer chemotherapy.
(ii) In 1967, Hiller et al. (11) synthesized the ﬁrst antican-
cer prodrug of 5-FU, FT. A historical encounter with FT
occurred in June 1969 when Dr Y. Kobayashi (Taiho
Pharmaceutical Co., Ltd, Tokyo, Japan) paid a visit to
President Dr N.N. Blokhin at the Cancer Research Center
USSR, Academy of Medical Science, Moscow, USSR.
Dr Kobayashi looked at an ampule on the table and asked
him the following question, ‘What is this ampule?’. Dr
Blokhin then replied, ‘This is a derivative of 5-FU that was
synthesized at the Latvian Institute of Organic Synthesis,
USSR.’ Dr Kobayashi, strongly attracted by the derivative,
received a sample for preclinical studies and introduced FT
into Japan in December of that year to initiate the joint
development of the drug. This encounter really triggered the
development of FT to UFT, and then to S-1.
In 1970, FT was initially introduced as an injectable drug.
However, the drug provoked adverse reactions, e.g. nausea,
vomiting, eruption and central nervous system (CNS) dis-
turbances, prior to exerting its clinical effects, making long-
lasting treatment difﬁcult. Therefore, FT failed to provide
clinical effects in most patients. Since FT had been found to
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the presence of NADPH by Toide et al. (12), Drs
K. Kimura, S. Fujii and T. Taguchi considered that its oral
administration would not adversely affect the GI tract in
a direct manner and proposed the change of its route of
administration, i.e. from the intravenous to the oral route.
That was the moment when FT marked the ﬁrst step as an
oral anticancer agent.
FT is the ﬁrst masked form oral anticancer agent that
gradually releases 5-FU by the action of a liver microsomal
P450 enzyme CYP2A6 (12,13). So far, CYP2A6 has been
clariﬁed to show racial differences in enzyme activity among
black, Caucasian and yellow populations and to have higher
activity in the Caucasian population than in the yellow popu-
lation (14). It would not be an exaggeration to say that such
change to the oral route made it possible to develop S-1
from UFT subsequently. In fact, the injection of FT was
developed up to Phase II in the USA. However, its develop-
ment was discontinued due to insufﬁcient effects and to the
high incidences of CNS disturbances (15).
Nevertheless, plasma concentrations of 5-FU after oral
administration of FT were lower than those obtained by CVI,
a regimen that was considered best for 5-FU administration,
and failed to reach the effective blood drug concentration.
Therefore, improvements were attempted to elevate plasma
concentrations of 5-FU in order to enhance further the anti-
tumor activity of FT.
(iii) In 1976, Fujii et al. (16) invented an oral anticancer
agent, UFT
w, and veriﬁed that uracil inhibits the degradation
of 5-FU and determined to combine uracil with FT.
Subsequently, Fujii et al. found the optimal molar ratio for
UFT, i.e. 4 mol of uracil and 1 mol of FT, and thus success-
fully elevated the initial plasma concentrations of 5-FU after
oral administration of UFT. The combination of uracil
allowed UFT to exhibit more potent antitumor activity than
does FT. Nevertheless, UFT, an improvement from FT, also
failed to sustain the effective plasma concentration of 5-FU
for as a long time as the CVI regimen could provide. Hence,
improvements were attempted to sustain plasma concen-
trations of 5-FU at equal to or greater than its plasma
concentrations that could be obtained by the CVI regimen.
We then initiated the exploration of an inhibitor of dihydroxy
pyrimidine dehydrogenase (DPD), a 5-FU-degrading
enzyme, that was more potent than uracil.
In 1984, consequently, we discovered a potent 5-FU-
degrading enzyme inhibitor CDHP, a pyridine derivative
Table 1. Timeline: from the discovery of 5-FU to the development of S-1 (TS-1
w)
Years Events
1957 (i) Synthesis of 5-FU and discovery of its antitumor activity by Dushinsky et al. (3).
1967 (ii) Synthesis of FT by Hiller et al. (11) at the Latvian Institute of Synthesis, USSR
June 1969 Encounter with FT (Futraful
w): Y. Kobayashi, the President of Taiho met with Blokhin the President Cancer Research Center, USSR
Academy of Medical Science
December 1969 Introduction of FT by Taiho Pharmaceutical Co., Ltd
1970 Development of FT from the intravenous to oral agent by Kimura, Fujii and Taguchi
1976 (iii) Invention by Fujii et al. (16) of UFT
w (oral combination drug), FT:Ura ¼1:4
1984 Discovery of an inhibitor for 5-FU catabolic enzyme, CDHP by Tatsumi et al. (17)
May 1987 Discovery of Oxo that reduces 5-FU-induced gastrointestinal toxicities by Shirasaka et al. (18)
November 1990 Establishment of the S-1 project by Y. Kobayashi
January 1991 (iv) Invention of S-1 by Shirasaka et al. (19) S-1, FT:CDHP:Oxo ¼1:0.4:1
March 1991 Onset of preclinical studies
November 1992 Onset of Phase I clinical trials
March 1994 Onset of Phase II clinical trials
November 1997 NDA of S-1 for gastric cancer
January 1999 Approval of S-1 (TS-1
w) for gastric cancer through the priority review system (20,21)
April 2001 Approval of S-1 for head and neck cancer (22)
December 2003 Approval of S-1 for colorectal cancer (23,24)
December 2004 Approval of S-1 for non-small cell lung cancer (25)
November 2005 Approval of S-1 for breast cancer (26)
August 2006 Approval of S-1 for pancreatic cancer (27)
August 2007 Approval of S-1 for biliary tract cancer (28)
2008 Phase III studies of S-1 (29,30)
FT, tegafur; CDHP, 5-chloro-2,4-dihydroxypyridine; Oxo, potassium oxonate; NDA, new drug application.
4 Development and usefulness of S-1 (TS-1
w)(17). Long-lasting high plasma concentrations of 5-FU were
thus obtained.
High plasma concentrations of 5-FU in the long-term were
predicted to induce strong myelotoxicity and GI toxicities.
Therefore, we initiated the exploration of a substance that
might reduce GI toxicities. In 1987, we discovered Oxo that
has reducing activity principally on GI toxicities induced by
5-FU (18).
In those days, I had already invented a combination drug
among FT, CDHP and Oxo.
In November 1990, Dr Kobayashi proposed the establish-
ment of the S-1 Project (leader: Shirasaka) that comprised
26 members. At that time, the following negative views
arose on the project inside and outside the company: (a)
5-FU is obsolete, (b) it is difﬁcult to obtain approval for a
three-component combination drug and (c) enormous costs
and much time are required to perform the preclinical safety
studies of a three-component combination drug. Despite
these negative views, in-house consent was obtained because
of the established project. Thereafter, S-1 was developed
smoothly up to its clinical trials.
(iv) In 1991, we invented a three-component combination
drug, S-1 (TS-1
w) (19). S-1 is an oral anticancer agent that
combines FT, CDHP and Oxo at a molar ratio of 1:0.4:1 and
that concurrently has dual actions, i.e. effect-enhancing
activity and adverse reaction-reducing activity.
Preclinical concepts built in basic research were thus also
proved in clinical trials. Therefore, the new drug application
(NDA) for S-1 was ﬁled in November 1997 and was then
approved for gastric cancer in January 1999 through the pri-
ority review system (20,21). By that year,  30 years elapsed
since the historical encounter of Dr Kobayashi with FT in
Moscow. Subsequently, S-1 was approved for the following
six cancers from 2001 to 2007: head and neck (22), colorec-
tal (23,24), non-small cell lung (25), breast (26), pancreatic
(27) and biliary tract cancers (28). S-1 is currently applied to
acquire its expanded indications to treat cervical and prostate
cancers. The Phase III clinical trials of S-1 have reported the
usefulness of S-1 as postsurgical adjuvant chemotherapy for
gastric cancer (29) and its combination with cisplatin
(CDDP) for advanced gastric cancer (30).
METABOLISM OF 5-FU
I provide a succinct overview of the metabolism of 5-FU,
the core drug of this review.
Figure 1 shows the metabolic pathways of pyrimidine
nucleotides and 5-FU.
MAIN SITES OF ACTION OF 5-FU
Approximately 90% of 5-FU that was administered to the
patient is degraded in F-b-Ala by DPD in the liver and
excreted as F-b-Ala in the urine within 24 h after i.v. bolus
administration (31) and  10% of 5-FU is converted to
F-RNA and FdUMP. 5-FU is so similar to uracil in chemical
structure that it is recognized and metabolized by all
enzymes that are involved in the uracil metabolism except
for one, dTMP synthase. Therefore, 5-FU can be converted
through the intermediates FUrd, FUMP, FUDP and FUTP to
F-RNA that induces the metabolic abnormality in RNA and
the inhibition of the RNA synthesis and that exhibits cyto-
toxicity. 5-FU can also be converted into FdUDP from
FUDP by ribonucleotide reductase and then to FdUMP.
Furthermore, dTMP synthase binds to FdUMP and forms a
ternary complex with reduced folate (Fig. 1). However, the
complex cannot perform its enzyme reaction and remains
irreversibly bound to FdUMP. Consequently, FdUMP inhi-
bits dTMP synthase activity, inhibits DNA synthesis, and
exhibits cytotoxicity. Figure 2 summarizes the biological
actions of Ura, CDHP, Oxo on the metabolic pathways of
5-FU and the conversion of FT to 5-FU.
5-FU is anabolized to FdUMP in various tissues. FdUMP
in tumor cells, the GI tract and bone marrow shows antitu-
mor activity, GI toxicities (32) and myelotoxicity (33),
respectively.
F-b-Ala induces all sorts of toxicities because of its long
blood retention time (31). In fact, F-b-Ala is known to cause
cardio (34) and neurotoxicities (35). Recently, the possible
development of HFS due to the degradation product of 5-FU
was reported by Yen-Revollo et al. (36).
INVENTION OF S-1
DISCOVERY OF CDHP
To utilize 5-FU efﬁcaciously, it is indispensable to inhibit
the degradation of 5-FU by DPD. Hence, we conducted
enzymological studies on DPD inhibitors. In 1984, conse-
quently, we discovered CDHP as a novel compound with
potent DPD-inhibitory activity and whose enzymological
patterns show reversible competitive inhibition (17).
Figure 1. Metabolic pathways of pyrimidine nucleotides and 5-FU. Main
sites of action of 5-FU. 5-FU, 5-ﬂuorouracil; FdUMP, 5-ﬂuoro-20- deoxyuri-
dine 50-monophosphate; F-b-Ala, alpha-ﬂuoro-beta-alanine.
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to FdUMP and F-RNA that exhibit antitumor activity
and provoke adverse reactions, e.g. myelotoxicity and GI
toxicities. For the efﬁcacious use of 5-FU, therefore, it is
necessary to ﬁrst and strongly inhibit the 5-FU-degrading
enzyme in an attempt to elevate its antitumor activity.
Regarding the synthesis of a DPD inhibitor, we initiated the
synthesis of pyrimidine derivatives containing uracil and
expanded our research to the synthesis of barbituric acid and
pyridine derivatives before ﬁnally reaching the discovery of
a potent DPD inhibitor CDHP. The Ki values of CDHP and
Ura for DPD-inhibitory activity were 1   10
27 and 1.8  
10
25 M, respectively (Fig. 2). DPD-inhibitory activity inten-
siﬁed by  200-fold from pyrimidine derivatives (e.g. Ura)
to pyridine derivatives (e.g. CDHP). Pyridine derivatives
exhibited the most potent DPD-inhibitory activity. The fact
that a compound has potent DPD-inhibitory activity is an
important factor. However, the facts that a compound is a
competitive inhibitor of DPD and that it is safe are more
important than its efﬁcacy. Out of these derivatives,
CDHP—a novel highly safe pyridine derivative with a com-
petitive inhibition pattern and the fourth potency—was
selected as a component of S-1 (17).
FT plus CDHP whose inhibitory activity is 200-fold more
potent than uracil and UFT were administered orally to rats, and
plasma 5-FU concentrations were examined. As shown in
Fig. 3, plasma 5-FU concentrations increased markedly in the
combination of FT plus CDHP than in the combination of UFT.
The FT plus CDHP combination group showed the Cmax
value of 300 ng/ml or higher; the values were markedly
higher than those in the UFT group (37).
The FT plus CDHP combination group allowed us to
expect high anticancer activity. However, increased plasma
concentrations of 5-FU induced higher incidences of GI
toxicities and myelotoxicity. Therefore, the exertion of
its potent antitumor effect could not be expected unless
devising a scheme to reduce these toxicities.
Subsequently, we initiated the examination of the
mechanism to reduce the degradation of 5-FU in the liver
by CDHP, resulting in (i) enhancement of the antitumor
activity of 5-FU and (ii) reduced incidences of HFS, cardio-
toxicity and neurotoxicity induced by the drug.
DISCOVERY OF OXO
In 1965, Grant et al. administered Oxo intravenously to
cancer patients as an anticancer agent that inhibits orotate
phosphoribosyltransferase (OPRT) resulting from the
de novo biosynthesis of pyrimidine. However, Oxo showed
insufﬁcient antitumor activity (38). Furthermore, they did
not notice that Oxo reduces the incidences of GI toxicities
induced by 5-FU, presumably due to the route of adminis-
tration they selected—intravenous. Consequently, Oxo has
never been used as an anticancer agent thereafter.
Figure 3. Potent inhibitory activity of CDHP that is translated into
increased plasma 5-FU concentrations after oral administration of FT and
CDHP to rats as compared with FT and Ura (UFT) (19,39).
Figure 2. Biological actions of Ura, CDHP and Oxo on the metabolic pathways of 5-FU, as well as the conversion of FT to 5-FU. FT, futraful; CDHP,
5-chloro-2,4-dihydroxypyridine; Oxo, potassium oxonate.
6 Development and usefulness of S-1 (TS-1
w)In 1987, we administered Oxo orally to Yoshida sarcoma-
bearing rats in combination with 5-FU as part of preclinical
studies to seek a substance that reduces the incidences of
the GI toxicities induced by 5-FU. Consequently, we found
that: (i) Oxo inhibits OPRT in the small intestine not in
tumor and bone marrow tissues and (ii) orally administered
Oxo accumulates more intensively in GI tissues than in other
tissues (e.g. blood and tumor) of tumor-bearing rats. Oxo is
preferably distributed in the GI mucosa after oral adminis-
tration and inhibits 5-FU-induced GI toxicities (18).
Figure 4 shows the tissue distributions of
14C-Oxo after
oral administration to Yoshida sarcoma-bearing rats. High
concentrations of Oxo were distributed in the small and large
intestines in the long-term, and a very low concentration of
Oxo was distributed in the tumor.
5-FU is anabolized to FdUMP in actively dividing cells,
i.e. tumor cells, mucosal cells of the GI tract and bone
marrow cells. Therefore, we attempted to reduce the inci-
dences of adverse reactions of 5-FU, especially GI toxicities,
for the purpose of improving patient compliance.
The usefulness of Oxo to suppress vomiting and diarrhea
was examined in beagle dogs that have high susceptibility to
5-FU. As shown in Table 2, the group in which Oxo was
removed from S-1 showed the high incidences of vomiting
and diarrhea [7 of 11 (63.6%) and 10 of 11 (90.9%), respect-
ively], whereas the Oxo-containing S-1 group showed
marked improvements [1 of 11 (0.9%) and 1 of 11 (0.9%),
respectively] (37,39). This result led us to consider the
potential usefulness of S-1 in alleviating vomiting and
diarrhea also in clinical settings, thus allowing the patient to
take a meal normally and contributing to the improvement of
his/her quality of life (QOL).
STUDY OF THE MOLAR RATIOS AMONG FT, CDHP AND OXO
To determine the best molar ratio among FT, CDHP and
Oxo, it was of primary importance to consider balancing
efﬁcacy and toxicity. First, different moles (0, 0.2, 0.4, 0.6
a n d0 . 8 )o fC D H Pw e r ec o m b i n e dw i t h1m o lo fF T .T h e
suspension was administered orally for 7 consecutive days to
Yoshida sarcoma-bearing rats in which the tumor had been
transplanted 24 h previously. Animals were sacriﬁced on
Day 10 after the onset of oral administration to examine the
antitumor activity and toxicities of the combinations based
on tumor weight and body weight decreases against the
control group. Furthermore, the combinations at the above
molar ratios were administered orally to normal rats in a con-
current manner to measure plasma concentrations of 5-FU
on a time-course basis. Consequently, antitumor activity
approximated the peak at molar ratios of  1:0.4 between FT
and CDHP, and body weight decrease was least at a molar
ratio of 1:0.4 between FT and CDHP. Further increases in
molar ratios between FT and CDHP failed to enhance the
antitumor activity of 5-FU, and body weight decrease inten-
siﬁed. Furthermore, increases in the molar ratios between FT
and CDHP did not indicate increases in plasma 5-FU con-
centrations. The above results led us to determine the molar
ratio of 1:0.4 between FT and CDHP. Second, different
molar ratios (0, 0.5, 1 and 2) of Oxo were examined while
maintaining the ﬁxed molar ratio of 1:0.4 between FT and
CDHP. The antitumor activity of 5-FU did not reduce when
1 mol of Oxo was combined with FT and CDHP (1:0.4) but
markedly decreased when .1 mol of Oxo was combined.
Therefore, we determined the molar ratio of 1:0.4:1 for the
combination of FT, CDHP and Oxo. Concurrently with this
study, a study to examine the antitumor activity of 5-FU
similar to the above was conducted using different timings to
administer these three compounds. Consequently, balancing
efﬁcacy and toxicity was found best, especially when Oxo,
FT and CDHP were administered concurrently. Therefore,
these three compounds were formulated to combination
drugs in capsules to allow their simultaneous oral adminis-
tration in clinical trials (19,37).
PRECLINICAL STUDIES OF S-1
Preclinical studies to examine the anticancer activity of S-1
were conducted mainly in rats because rats precisely reﬂect
the effects and adverse reactions of 5-FU due to the sustain-
ment of plasma 5-FU concentrations for a longer time after
oral administration of S-1 than do mice.
We used an anticancer experiment system with Yoshida
sarcoma and administered S-1 orally for 7 consecutive days
Figure 4.
14C-oxonic acid concentrations in blood and tissues of Yoshida
sarcoma-bearing rats after oral administration of
14C-Oxo (potassium
oxonate) (18).
Table 2. Incidences of vomiting and diarrhea reduced by Oxo after oral
administration of FT and CDHP to beagle dogs (Refs 37,39)
Drug Dose
(mg/kg)
Duration
(day)
Animal
(n)
Vomiting
[n (%)]
Diarrhea
[n (%)]
FT plus CDHP
(1:0.4)
6 5 11 7/11 (63.6) 10/11 (90.9)
S-1 [FT plus
CDHP plus Oxo,
(1:0.4:1)]
6 5 11 1/11 (0.9) 1/11 (0.9)
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centrations of 5-FU. As shown in Fig. 5, S-1 showed a more
potent antitumor effect than UFT and indicated absolutely
no tumor proliferation at an FT dose of 20 mg/kg.
Furthermore, we administered S-1 orally at a dose level of
10 mg/kg, an FT dose level showing a treatment/control
(T/C)v a l u e(  0.5), to measure the tumor and plasma con-
centrations of 5-FU on a time-course basis. As shown in
Fig. 6, the Tmax of 5-FU was 2 h in both the plasma and
tumor. Plasma 5-FU concentrations persisted at 100 ng/ml or
higher up to 8 h after administration, while tumor concen-
trations of 5-FU persisted at 200 ng/g or higher up to 12 h
after administration. The results of these pharmacological
studies validated the potent antitumor activity of S-1 (19,37).
PHARMACOKINETIC CLINICAL TRIALS OF S-1 IN PATIENTS WITH
GASTRIC CANCER,C OLORECTAL CANCER AND BREAST CANCER
The early Phase II clinical trials of S-1 were completed.
These trials were conducted according to the recommended
regimen for S-1, i.e. S-1 80 mg/m
2/day, given orally twice
daily after breakfast and dinner for 28 consecutive days.
The initial dose of S-1 for each patient was determined
according to body surface area (BSA) as follows: for BSA
of ,1.25 m
2, 80 mg/day; for BSA of  1.25,1.5 m
2,
100 mg/day; and for BSA of  1.5 m
2,1 2 0m g / d a y .T w e l v e
patients were recruited to these trials: ﬁve with gastric
cancer (three of whom underwent total gastrectomy), four
with colorectal cancer and three with breast cancer. As
shown in Fig. 7, the pharmacokinetic parameters of 5-FU
in plasma were as follows: Cmax,1 2 8 . 5 +41.5 ng/ml; Tmax,
3.5+1.7 h; AUC0–14, 723.9+272.7 ng h/ml; and T1/2,
1.9+0.4 h. The 28-day consecutive oral regimen indicated
neither pharmacokinetic ﬂuctuations nor drug accumulation
(40). All the 12 patients showed plasma 5-FU concen-
trations of 60–200 ng/ml. The pharmacokinetics of orally
administered S-1 constantly provided plasma 5-FU concen-
trations that were almost equivalent to or higher than those
obtained by CVI of 5-FU (41). S-1 improves patient’s
QOL because of the following advantages: (i) being an
oral agent, thus releasing the patient from the restriction of
CVI and (ii) being administrable on outpatient settings.
Furthermore, Tmax for 5-FU in all the three patients who
underwent total gastrectomy (thick solid line) was 2 h,
being faster than 4 h in
non-gastrectomized patients. However, the AUC0–14h
values for 5-FU were 691 and 822.8 ng h/ml in patients
who did not have total gastrectomy and patients who
underwent the surgery, respectively. Therefore, no signiﬁ-
cant difference was found in AUC for 5-FU between these
patient groups.
In addition, a recent study (42) measured plasma 5-FU
concentrations after oral administration of S-1 to six patients
with gastric cancer before and after total gastrectomy.
Consequently, Tmax signiﬁcantly decreased from 4 h before
surgery to 3.3 h after surgery, and AUC0–10h for 5-FU sig-
niﬁcantly increased from 680 ng h/ml before surgery to
1030 ng h/ml after surgery. Studies (40,42) provided a con-
cordant interpretation that Tmax for 5-FU is decreased by
gastrectomy. AUC for 5-FU seems to tend to increase.
The above results suggested the usefulness of S-1 as post-
surgical adjuvant therapy for patients with gastric cancer.
Recently, its usefulness as postgastrectomy adjuvant therapy
for gastric cancer was demonstrated in a Phase III clinical
trial (29).
LATE PHASE II CLINICAL TRIALS OF S-1
Table 3 summarizes the results from the late Phase II clinical
trials of S-1 in patients with gastric, head and neck, colorec-
tal, NSCL, breast, pancreatic or biliary tract cancers at the
time of NDA. S-1 alone showed high overall response rates
for advanced and recurrent gastric, colorectal, pancreatic and
biliary tract cancers. S-1 is superior to the ﬁrst-line drug for
pancreatic cancer, gemcitabine (GEM) whose response rate
was 23.8% and whose median survival time (MST) was 170
days. A randomized clinical trial of 5-FU alone in patients
with advanced and recurrent pancreatic cancer has revealed
its usefulness in survival rate and clinical beneﬁt (43). S-1,
when combined with CDDP, showed a high response rate for
Figure 5. Antitumor activity of S-1 and UFT in Yoshida sarcoma-bearing
rats (19,37). T/C, treatment/control; UFT, FU and uracil.
Figure 6. 5-FU concentrations in plasma of and tumor in Yoshida sarcoma-
bearing rats after oral administration of S-1 (19,37).
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w)non-small cell lung cancer (NSCLC) and was effective also
for patients with taxane-resistant breast cancer. The possible
reasons to explain why S-1 has shown high response rates
for the six cancers are the following: (i) S-1 presents a high
rate of reaching cancer tissue through the long duration of
high plasma 5-FU concentrations and (ii) long-lasting treat-
ment with S-1, by which the cycles of 4-week consecutive
administration and 2-week drug withdrawal are repeated.
As shown in Table 4, the incidences of  Grade 3 adverse
reactions of S-1 in a total of 449 patients were not .10% in
the Phase II clinical trials, except for neutropenia (11.1%).
The incidences of  Grade 3 non-hematologic adverse reac-
tions, stomatitis, nausea, vomiting, diarrhea and anorexia,
were low because of the Oxo contained in S-1. HFS,
although not life-threatening, can severely disrupt the
patient’s daily life. Therefore, the fact that HFS was not
observed at all because of CDHP is noteworthy.
CLINICAL USEFULNESS AND FUTURE VISTAS
OF S-1
Approximately 30 years elapsed from the discovery of FT to
the development of S-1 through UFT, thus indicating the
evolution of drug development (UFT rather than FT and S-1
rather than UFT). As shown in Fig. 8, FT is used as an effec-
tor in all these drugs. Namely, the daily doses of FT in
routine medical care are 1200 mg/day (FT), 600 mg/day
(UFT) and 120 mg/day (S-1). Therefore, we successfully
reduced the total daily doses of FT to 1/10th the initial value
in 30 years. This extensive reduction in the total daily dose
of FT has allowed the efﬁcacious use of 5-FU to be extracted
from FT, the elevation of 5-FU efﬁcacy, and the reduction in
the incidences of adverse reactions of 5-FU. Therefore, S-1
may be considered patient-friendly drug.
As shown in Fig. 9, Yen-Revollo et al. (36) recently
reported in their review article that patients treated with
Figure 7. Plasma 5-FU concentrations in cancer patients after oral administration of S-1. Bold lines represent three patients who underwent total gastrectomy( 4 0 ) .
Table 3. Summary results from the late Phase II clinical trials of S-1 in Japan
Cancers Phases Response rate (CR plus PR/patient) Regimens MST (days) References
Gastric Late P II 49.0% (25/51) S-1 250 20
Late P II 40.0% (20/50) S-1 207 21
Head and neck Late P II 28.8% (17/59) S-1 344 22
Colorectal Late P II 35.5% (22/62) S-1 378 23
Late P II 39.5% (15/38) S-1 358 24
NSCL Late P II 47.3% (26/55) S-1 plus CDDP 334 25
Breast (taxane-resistant) Late P II 21.8% (12/55) S-1 470 26
Pancreatic Late P II 37.5% (15/40) S-1 269 27
Biliary tract Late P II 35.0% (14/40) S-1 286 28
Seven indications were approved in 1999–2007.
MST, median survival time; NSCL, non-small cell lung cancer; CDDP, cisplatin.
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developing HFS of all grades than patients who undergo
treatment with DPD inhibitor-containing ﬂuoropyrimidines.
The incidence of Grade 3/4 HFS was high when 5-FU was
given by CVI and oral capecitabine, while HFS did not
develop when UFT, S-1 and eniluracil were administered.
These results suggest that the decreased incidence of HFS
is presumably due to the limited production of degradation
products of 5-FU because CDHP potently inhibits the degra-
dation of 5-FU in the liver.
They concluded as follows: with the accumulating ﬁnd-
ings from clinical trials that show the beneﬁts of DPD inhi-
bition in decreasing the risk of HFS, consideration should be
given to changing the recommendations for the treatment of
cancer patients with ﬂuoropyrimidines to include DPD
inhibitor components as standard therapy.
S-1 AND LOW- OR HIGH-DOSE CDDP THERAPY
Scanlon et al. (44) discovered a synergic cytotoxic effect in
1983 when combining 5-FU with CDDP in in vitro studies,
while we did it in in vivo studies in 1993 (45) and 2000
(46). In low-dose FP therapy, CDDP is used not as an effec-
tor but as a modulator for 5-FU; the frequent dosing of
CDDP at a not greater than 1/10th the usual dose markedly
reduces the incidences of its adverse reactions while sustain-
ing its effects, allowing long-lasting treatment with 5-FU.
Since around 1990, the therapy has widely been accepted
and performed in routine medical care in Japan (47,48).
Recently, low-dose FP therapy in which S-1 is used instead
of 5-FU given by CVI has come into wide use as a patient-
friendly therapeutic modality for outpatients with cancer
(49,50). This regimen requires no hydration, enables treat-
ment in outpatient settings at low medical costs.
There are two published articles for the combination
therapy of S-1 and CDDP in Japan. One of them has
described a randomized Phase III clinical trial of S-1 and
high-dose CDDP [S-1 plus cisplatin versus S-1 alone for
ﬁrst-line treatment of advanced gastric cancer (the SPIRITS
trial)] in patients with advanced gastric cancer, in which
CDDP was used as the effector for 5-FU (50,51). Another
has described a retrospective study of low-dose therapy in
outpatients with advanced and recurrent gastric cancer,
in which CDDP was used as the modulator for 5-FU (52). In
the former study, S-1 80 mg/m
2 was administered orally
twice daily for 3 consecutive weeks followed by 2-week
drug withdrawal and CDDP 60 mg/m
2 was given by the
intravenous drip infusion on Day 8 within a 5-week cycle,
and S-1 alone 80 mg/m
2 was administered orally for 3 weeks
followed by 2-week drug withdrawal within a 5-week cycle.
In the latter study, S-1 80 mg/m
2 was administered orally for
4 weeks followed by 2-week drug withdrawal within a
6-week cycle. CDDP 6 mg/m
2 was administered by intrave-
nous drip infusion for 30 min twice a week (Days 1 and 4)
within the 6-week cycle. These two clinical trials cannot be
compared directly, especially for efﬁcacy, because the
former study is the SPIRITS trial in which the S-1 and high-
dose CDDP group enrolled 148 patients and the latter is a
retrospective study in which the S-1 and low-dose CDDP
group enrolled 32 patients. Table 5 indicates that the combi-
nation therapy of S-1 and low-dose CDDP is at least equival-
ent to that of S-1 and high-dose CDDP in efﬁcacy and MST.
These two clinical trials can be compared to a certain extent
with respect to the overall incidences of  Grade 3 adverse
reactions that cause the greatest distress to the patient.
Namely, 15.6% (5 of 32) in the S-1 and low-dose CDDP
group; 66.9% (99 of 148) in the S-1 and high-dose CDDP
group; and 24.7% (37 of 150) in the S-1 alone group. The
incidences of  Grade 3 non-hematologic toxicities (i.e.
anorexia and nausea/vomiting) in these groups were 0 and
0%, 30.4 and 15.6% and 6 and 3%, respectively. S-1 and
high-dose CDDP elicited slight concern because they pre-
sented an  70% incidence of  Grade 3 non-hematologic
adverse reactions that constituted great factors leading the
patient to deny the further ingestion of the drugs and
required the hydration of the patient by hospitalization,
while S-1 and low-dose CDDP therapy did not provoke
Table 4. Major adverse reactions in the late Phase II clinical trials of S-1
(Refs 20–28)
Grade  G3 (%) (n ¼ 449)
12 3 4
Leukopenia 114 95 12 4 3.6
Neutropenia 71 91 46 4 11.1
Thrombocytopenia 87 19 3 5 1.8
Anemia 82 102 32 5 8.2
Stomatitis 84 17 1 0 0.2
Nausea 102 20 10 0 2.2
Vomiting 40 27 9 0 2.0
Diarrhea 61 31 14 0 3.1
Anorexia 107 60 20 1 4.7
Hand–foot syndrome 12 7 0 0 0
Hand–foot syndrome, causing a great discomfort of patients, was not
observed.
Figure 8. Reductions in total daily doses of FT in an attempt to establish
patient-friendly formulations.
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w)Figure 9. Incidences of hand–foot syndrome (HFS) in patients during treatment with different ﬂuoropyrimidines. (A) Patients treated by continuous infusion of
5-FU or capecitabine are at signiﬁcantly higher risk of developing all grades of HFS as compared with patients on bolus 5-FU or combination therapy containing
a DPD inhibitor (UFT, S-1, or 5-FU/eniluracil). (B) Grade 3 or 4 symptoms were extremely rare in patients who received UFT, S-1, or 5-FU/eniluracil (36).
Table 5. Efﬁcacies and adverse reactions of S-1 alone and of S-1 in combination with low- or high-dose CDDP
A retrospective study (Ref. 52) SPIRITS trial (Phase III) (Refs 50,51)
S-1 and low-dose CDDP, n ¼ 32 S-1 and high-dose CDDP, n ¼ 148 S-1 alone, n ¼ 150
Efﬁcacy
Response rate 78.1% (25/32) 54.0% (47/87) 31.1% (33/106)
Prior chemotherapy
Absent 80.0% (16/20) 54.0% (47/87) 31.1% (32/106)
Present 75.1% (9/12) — —
MST 12 months 13 months 11 months
1-year survival 48.1% 54.1% 46.7%
2-year survival 23.0% 23.6% 15.3%
Adverse events
Total ( G3, %) 15.6 (5/32) 66.9 (99/148) 24.7 (37/150)
Hematologic
Leukocytopenia 0 11.5 2.0
Anemia 0 25.7 4.0
Thrombocytopenia 12.5 5.4 0
Non-hematologic
Nausea/vomiting 0 15.6 3.3
Anorexia 0 30.4 6.0
Fatigue 0 4.1 1.3
HFS 0 0 0
Renal dysfunction 3.1 0 0
Convenience and quality of life (QOL) Hydration (2)
Outpatient
Hydration (þ)
Hospitalization (3–4 days/5 weeks)
Hydration (2)
Outpatient
SPIRITS, S-1 plus cisplatin versus S-1 alone for ﬁrst-line treatment of advanced gastric cancer; CDDP, cisplatin; MST, median survival time; HFS, hand–foot
syndrome.
Jpn J Clin Oncol 2009;39(1) 11 Grade 3 non-hematologic adverse reactions at all and
required no hydration, although the patient needed to visit
the hospital twice a week to receive low-dose CDDP.
Therefore, S-1 and low-dose CDDP therapy allows both
long-lasting treatment in outpatient settings and survival
beneﬁt at low medical costs.
BIOLOGICAL THEORY OF THE ALTERNATE-DAY S-1 REGIMEN
In 1963 and later, Lipkin et al. (53), Clarkson et al. (54) and
Cronkite et al. (55) reported differences in cell cycles
between cancer cells and normal cells (bone marrow cells,
GI mucosal cells and cells with rapid cell division). As
shown in Table 6, the generation time of normal cells (bone
marrow and GI mucosal cells) lasts for as very shortly as
0.42–1.32 days. Therefore, 1-day drug withdrawal allows the
emergence of unexposed normal cells by  50%. On the
other hand, the generation time of cancer cells was 3.8–5
days, and the duration of the S-phase during which 5-FU
acts predominantly was one or more days (17–60 h) in most
cancer cells. Therefore, the repetition of 1-day drug
withdrawal leads to the sustainment of the anticancer
activity of 5-FU. By making the use of this large difference
in cell cycles, we invented a new dosing schedule for 5-FU,
an antimetabolic agent with the strong time-dependent mode
of action.
We then examined the alternate-day S-1 regimen
(alternate-day dosing or dosing on Monday, Wednesday and
Friday per week). We have reported these theories and
practices in in vitro studies (56,57) in vivo studies (57) and a
retrospective clinical trial (58). Based on the above theories,
alternate-day exposure to 5-FU did not reduce its cytocidal
activity in the in vitro studies (56,58). In the in vivo study
using nude mice, the anticancer activity of S-1 given by the
alternate-day regimen was equivalent to or better than that of
daily dosing. Furthermore, the alternate-day S-1 regimen
markedly reduced myelotoxicities and GI toxicities (58). The
fundamental regimen in clinical settings was started with the
recommended daily dosing of S-1 for 4 weeks followed by
2 weeks of drug withdrawal. S-1 was administered orally at
40 mg/m
2 twice daily after a meal. Grade 2 or higher
adverse reactions and Grade 1 non-hematologic toxicities
made patients unwilling to undergo chemotherapy con-
tinuously, and the daily regimen was converted to the
alternate-day regimen (40 mg/m
2 twice daily on an
alternate-day basis) based on the above theory.
The alternate-day regimen was equivalent to or better than
the daily regimen in patients with inoperable or advanced
gastric cancer in a clinical trial (58). A fact of particular
note is that the incidences of adverse reactions remarkably
differ between these regimens. As shown in Table 7, the
daily regimen was continued in 20 among 92 patients; the
regimen was discontinued in 72 among 92 patients due to
 Grade 1 adverse reactions and was converted to the
alternate-day regimen after about 1 week of drug withdrawal.
The incidences of adverse reactions that developed in these
72 patients were compared before and after the conversion.
After the conversion, Grade 1 or 2 leukopenia/neutropenia
and  Grade 3 diarrhea and pigmentation did not develop.
The total numbers of Grade 3, 2 and 1 adverse reactions
Table 6. Comparisons of generation time (TG) and of the durations of the
S-, G2-, M- and G1-phases between cancer and non-cancer cells
TG (days) S (h) G2 (h) M (h) G1 (h)
Cancer cells (diagnosis) (53)
Endometrial cancer 4.6 60 4 .14 8
Ovarian cancer 5 28 8 1 84
Ovarian cancer 5 34 6 1.4 72
Gastric cancer 3 20 3 .14 8
Gastric cancer 4.6 32 5 1.1 72
Lymphosarcoma 3.8 17 2 .17 2
Non-cancer cell (52)
Stomach 0.42 9–14 2 1 1
Ileum 0.63 11 2 1 2
Colon 0.67 14 1–2 1 1–2
Rectum 0.42 9–10 2 1 2
Myeloblast (54) 1.32 — — — —
TG, generation time; S, synthesis phase; G2, gap 2 phase; M, mitosis phase;
G1, gap 1 phase.
Table 7. The incidences of adverse reactions in patients with advanced
gastric cancer who were treated by the daily regimen of S-1 (n ¼ 92) and
then by the alternate-day regimen of S-1 (n ¼ 72) (Ref. 58)
Adverse reactions Daily regimen
(n ¼ 92)
a
Alternate-day regimen
(n ¼ 72)
b
G1, 36 (50%); G2, 33
(46%); G3, 3 (4%)
G1, 5 (7%); G2, 2
(3%)
G1 G2 G3 G4 G1 G2 G3 G4
Leukopenia/neutropenia 5 11 0 0 1 0 0 0
Anemia 1 1 0 0 0 0 0 0
Liver dysfunction 5 4 1 0 0 0 0 0
Renal dysfunction 2 1 0 0 0 0 0 0
General fatigue 14 4 0 0 0 0 0 0
Diarrhea 12 7 1 0 1 1 0 0
Pigmentation/dermatitis 12 5 1 0 1 1 0 0
Nausea/vomiting 11 4 0 0 2 0 0 0
Appetite loss 9 5 0 0 0 0 0 0
Stomatitis 5 0 0 0 0 0 0 0
Taste alteration 4 0 0 0 0 0 0 0
Herpes zoster 0 1 0 0 0 0 0 0
Others 5 1 0 0 0 0 0 0
G, grade.
aMean duration of treatment 47 days,
b272 days. Overlapped
toxicities developed in some patients.
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respectively. Furthermore, the mean duration of treatment
was 47 days in 92 patients who underwent the daily regimen
and was 272 days in 72 patients who underwent the
alternate-day regimen (57). The disappearance of hematolo-
gic toxicities allows long-lasting treatment while sustaining
the efﬁcacy of 5-FU. The elimination of Grade 1/2 adverse
reactions, e.g. fatigue, diarrhea, pigmentation/dermatitis,
nausea/vomiting, appetite loss, stomatitis and taste alteration,
permits patient compliance and makes long-lasting treatment
possible. The alternate-day S-1 regimen was at least equival-
ent to its daily regimen with respect to efﬁcacy. Thirty-ﬁve
of 42 curability C patients underwent the alternate-day S-1
regimen and had an MST of 383 days. On the other hand,
six of 23 curability C patients underwent the daily regimen
of S-1 and had an MST of 274 days (58).
Retrospective clinical studies on the alternate-day S-1
regimen, on the twice-a-week administration of CDDP,
and on the once-a-week administration of paclitaxel (TXL)
were conducted in patients with advanced pancreatic (59),
colorectal (60) and gastric (61) cancers and in patients with
early gastric cancer (62). MST was extended considerably
in all these cancers, and the incidences of  Grade 1 non-
hematologic adverse reactions were very low. Consequently,
long-lasting treatment was possible.
CLINICAL IMPORTANCE OF GI TOXICITIES
The GI tract, especially the small intestine, has drawn much
attention as an organ that plays a major role in the immune
function of the human body since 1997. Furthermore, enteral
nutrition through the small intestine has been evidenced to be
superior to central venous nutrition in sustaining intestinal
functionality for patients who are no longer capable of
ingestion. Animals fed by total parenteral nutrition only had a
signiﬁcantly fewer number of gut-associated lymphoid tissue
lymphocytes compared with that of chow-fed control animals.
The number of Peyer’s patches increased after a single day of
refeeding, returning to their normal account by 48 h thereafter
(63,64). Therefore, the alleviation of GI toxicities to a level at
which treatment can be conducted while the patient continues
to have a meal not only means the suppression of diarrhea or
vomiting, but is also crucially important in improving
immune function of the human body and conducting long-
lasting treatment. Most anticancer drugs induce immunosup-
pression as an adverse reaction. We have reported on
5-FU-induced immunosuppression in a preclinical study (65).
Body weight of rats treated with S-1 (FT plus CDHP plus
Oxo) for seven consecutive days was signiﬁcantly higher than
that of rats treated with FT plus CDHP for a similar period.
The number of peripheral leukocytes was signiﬁcantly higher
in S-1-treated rats than that FT plus CDHP-treated rats. This
suggests that Oxo in S-1 may reduce the suppression of antitu-
mor immunity induced by 5-FU.
CONCLUSION
5-FU is currently used as a core drug in the widely accepted
international standard regimes to treat GI cancers. All these
therapeutic modalities are the combinations of three or more
existing anticancer agents and their combinations with
recently developed molecular target agents. Combination
therapy is now a predominant approach in cancer chemother-
apy. Most recent combination studies of S-1 with CDDP,
CPT-11, TXL and other anticancer agents indicate the
crucial importance of exploring the combination between the
best partner drug and S-1: (i) allows long-lasting combi-
nation therapy in an attempt to validate a therapeutic
modality that is useful for cancer patients, (ii) prolongs the
treatment period without increasing the incidences of non-
hematologic toxicities that are most distressful for them and
(iii) confers survival beneﬁt to cancer patients.
‘S-1 and low-dose CDDP therapy’ and ‘alternate-day S-1
regimen’ may be considered as the most patient-friendly thera-
pies available to date that allow long-lasting treatment that
provokes no, or little, hematologic toxicities and induces only
 Grade 1 non-hematologic toxicities. I am fully conﬁdent that
‘balancing between the efﬁcacy and toxicity of an anticancer
agent, conferring survival beneﬁt to cancer patients’ will deﬁ-
nitely contribute to their routine medical care.
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